ClinicalTrials.gg
CompletedNCT04470050Updated Aug 11, 2026Results posted

Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal

A Phase 1/2 interventional study of Dexmedetomidine and Placebo in Opioid Withdrawal, sponsored by BioXcel Therapeutics Inc. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by BioXcel Therapeutics Inc · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,222 studies in Opioid-Related Disorders with a site in United States — 245 open to participants now, 315 under way, 18 of them phase 3. Opioid-Related Disorders · United States.

Enrollment
227th of 1,097
225 · median 56
Started
2020
with 93 others
Phase 1/2
30 of 1,222
4 open now
Registered
671st of 1,222
by date

Among the 1,222 studies in Opioid-Related Disorders with a site in United States, this one is the 227th largest by enrollment of the 1,097 interventional ones that give a count, is one of 94 that started in 2020, is one of 30 in phase 1/2, and was the 671st registered.

Opioid-Related Disorders

1,473 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

245 of the 1,222 studies in Opioid-Related Disorders with a site in United States are open now. Recruiting first, the newest first:

240 more — sign in →

All 245 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 210 Opioid-Related Disorders studies recruiting now, 122 (58%) set no upper age limit and 74 (35%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,222 studies in Opioid-Related Disorders with a site in United States, or all of them as a file.
02

Study summary

This Phase 1b/2 inpatient study assessed the safety, pharmacokinetics, and early signs of efficacy of escalating doses of BXCL501 versus placebo following discontinuation of morphine maintenance. The opioid (morphine) maintenance phase (Phase 1b) included Days 1-5; the randomized BXCL501/placebo phase (Phase 2) included Days 6-12. The randomized phase was followed by 2 sequential days, Days 13 and 14, utilizing treatment of BXCL501-placebo sublingual films and morphine-placebo capsules for all subjects who remained in the study.

Read the detailed description

This Study included two phases, Phase 1b and Phase 2. Phase 1b was the morphine maintenance phase, Days 1 through 5 and Phase 2 was the randomized, double-blind, placebo-controlled, ascending-dose study of BXCL501 sublingual films on Days 6-12 to treat symptoms of acute opioid withdrawal in patients with opioid use disorder who are/were physically dependent on opioids. Day 12 was followed by 2 sequential days (Days 13 and 14) of BXCL501 vs. placebo and morphine vs. placebo treatment for all subjects who remained in the study.

After a 30-day screening period, eligible male and female adult subjects with Opioid Use Disorder (OID) who were physically dependent on opioids and were not seeking treatment for opioid withdrawal symptoms were admitted to an inpatient unit. The opioid maintenance phase of the study (Phase 1b, Days 1-5) began on Day 1 and continued through Day 5. Approximately 225 subjects were enrolled in the Phase 1b study in cohorts (approximately 25 subjects/cohort). All subjects enrolled in the Phase 1b portion of the study received oral morphine capsules. The total dose of morphine during the opioid maintenance phase varied at the discretion of the investigator, ranged between 120 mg and 150 mg per day, depending on patients abuse history and need for higher dose to stabilize withdrawal symptoms. In addition, these subjects received placebo sublingual films approximately 12 hours apart to simulate and thus blind treatment of BXCL501 during Phase 2 of the study (Days 6-12).

Abrupt discontinuation of active morphine began on Day 6 (Phase 2) and subjects were randomized in a 4:1 ratio to receive either BXCL501 sublingual films or placebo sublingual films, respectively. 135 subjects enrolled/rolled over from the Phase 1b portion of the study into the randomized, double-blind, placebo-controlled portion of the study (Phase 2). Subjects were treated according to their assigned, randomized treatment from Day 6 through Day 12. Treatment was administered approximately 12 hours apart at approximately 8am (±30 minutes) and 8pm (±30 minutes); the 2nd dose (evening dose) was administered only to subjects that were hemodynamically stable, not hypotensive (must be greater than 110/70 diastolic/systolic), and not bradycardic (must be greater than 55 beats per minute (bpm)). Subjects were not given the second dose if they were orthostatic (a drop of 20 points in either systolic blood pressure (SBP) or 10 points in Diastolic Blood Pressure (DBP)) or if they were experiencing an Adverse Event (AE) that when assessed by the Investigator. If a subject experienced SBP \<90 mmHg; or DBT \<60 millimeters of mercury (mmHg); or Heart Rate (HR) \<50 bpm, immediately prior to the next dose, administration of the study medication for that subject was withheld until resolution of the BP and HR parameters. The administration hold did not exceed 2 hours. Safety and tolerability were monitored continuously and summarized upon completion of each cohort by medical safety review.

Studies of opioid withdrawal with placebo arms are likely to have high dropout rates, thus, the dropouts prior to Day 6 could be replaced to ensure enough sample size entering the treatment phase in Phase 2. Dropouts after Day 6 were not to be replaced. The study was intended to be flexible and adaptable, and as such, the dosing frequency, the doses, and the number of cohorts of BXCL501 allowed for change based on ongoing safety review and medical monitoring of safety, tolerability, and efficacy data after each dose-escalating cohort.

Phase 2 evaluated 6 cohorts (n=25 subjects per cohort according to the 4:1 randomization ratio; n= 20 active BXCL501 and n=5 placebo). The following doses were administered: 30 µg (Cohort 1), 60 µg (Cohort 2), 90 µg (Cohort 3), 120 µg (Cohort 4), and 180 µg (Cohort 5). The dose for Cohort 6 (240 μg) was determined from data acquired from Cohorts 1-5 and Cohort 6 was activated prior to the end of the study.

Other evaluations during the study included establishing the preliminary efficacy of multiple BXCL501 doses relative to placebo and evaluation of pharmacokinetics (PK) in subjects undergoing opiate withdrawal.

03

Conditions studied

  • Opioid Withdrawal

Keywords

  • Opioid
  • Opioid Addiction
  • Opioid Dependance
  • Opioid Withdrawal Symptoms
  • Opioid Withdrawal Syndrome
  • Morphine Addiction
  • delta-opioid receptors
  • Inhibition of nociceptive afferent neurons (PNS System)
  • Reduction of nociceptive transmission
  • Activation of descending inhibitory pathways (CNS System)
  • Analgesic Opioids
  • Drug craving
  • μ-δ-opioid (Mu-Delta) receptor
  • μ-binding (Mu receptors)
  • afferents within laminae I and II
  • κ-opioid receptor (KOR)
  • δ-opioid receptor (DOR) agonist
  • (+)-pentazocine
  • σ receptor antagonists
  • Downstream involvement of the σ receptor
  • Increase phosphorylation in p38 MAPK
  • IL-10
  • Activation of IL-12
  • IL-12 increase in T-cell immune response
  • pentacyclic 3°amine (alkaloid)
  • stereogenic centers
  • tetrahydroisoquinoline reticuline
  • CPY2D6
  • benzylisoquinoline alkaloid
  • p38 MAPK-dependent pathway
  • kappa-opioid receptors
  • Short Opiate Withdrawal Scale (SOWS)-Gossop
  • Clinical Opiate Withdrawal Scale (COWS)
  • Agitation and Calmness Evaluation Scale (ACES)
  • Discontinuation of Morphine Maintenance
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects who are 18 years of age to less than 65 years of age.
  2. Meets criteria for moderate to severe opioid use disorder as per , Fifth Edition (DSM-5) criteria and confirmed by the Mini International Neuropsychiatric Interview (MINI) with physiological dependence as evidenced by a Clinical Opiate Withdrawal (COWS) score of >5 or a positive naloxone challenge upon admission on Day 1.
  3. Subjects who can read, understand, and provide written . Women of must have a negative pregnancy test and agree to be abstinent or use an acceptable method of for the duration of the study.

Exclusion criteria

Exclusion Criteria

  1. Positive urine pregnancy test at screening or when tested or currently breast feeding.
  2. history of cardiac disease, screening and baseline heart rate of \<55 beats per minutes or systolic blood pressure \<110 mmHg or diastolic blood pressure \<70 mmHg.
  3. History or presence of a significant medical disease or disorder which, in the opinion of the investigator, increases the risk or may confound the interpretation of study measures, as confirmed by screening laboratory results.
  4. Hepatic dysfunction (marked by ascites, or >10% above the [ULN] or liver function tests >3 x ULN) at the screening visit.
  5. Acute active or C as evidenced by positive serology and (AST)/alanine aminotransferase (ALT) >2 x ULN.
  6. Clinically significant abnormal findings such as second- or third-degree heart block, uncontrolled arrhythmia, or (Fridericia correction formula) interval >450 msec for males, and >470 msec for females at screening or prior to dosing.
  7. Any psychiatric disorder that would compromise ability to complete study requirements.
  8. Currently meets criteria for substance abuse disorder, moderate or severe for any substance other than opioids, caffeine, or nicotine and/or current physical dependence on drugs that pose risk of withdrawal that requires medical management such as alcohol or benzodiazepines.
  9. History of suicidal behavior within the last 1 year prior to screening.
  10. Participation in a clinical trial of a non-FDA-approved pharmacological agent within 30 days prior to screening.
  11. Use of any excluded medication at screening or anticipated/required use during the study period.
  12. Subjects with a history of intolerance to morphine.
  13. Any finding that, in the view of the principal investigator, would compromise the subject's ability to fulfill the protocol visit schedule or visit requirements.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    Cohort 1- Dexmedetomidine (30 Micrograms) vs. Placebo

    Sublingual film containing 30 Micrograms Dexmedetomidine or Placebo Sublingual film

    Drug: Dexmedetomidine · Drug: Placebo

  • Experimental
    Cohort 2- Dexmedetomidine (60 Micrograms) vs. Placebo

    Sublingual film containing 60 Micrograms Dexmedetomidine or Placebo Sublingual film

    Drug: Dexmedetomidine · Drug: Placebo

  • Experimental
    Cohort 3- Dexmedetomidine (90 Micrograms) vs. Placebo

    Sublingual film containing 90 Micrograms Dexmedetomidine or Placebo Sublingual film

    Drug: Dexmedetomidine · Drug: Placebo

  • Experimental
    Cohort 4- Dexmedetomidine (120 Micrograms) vs. Placebo

    Sublingual film containing 120 Micrograms Dexmedetomidine or Placebo Sublingual film

    Drug: Dexmedetomidine · Drug: Placebo

  • Experimental
    Cohort 5- Dexmedetomidine (180 Micrograms) vs. Placebo

    Sublingual film containing 180 Micrograms Dexmedetomidine or Placebo Sublingual film

    Drug: Dexmedetomidine · Drug: Placebo

  • Experimental
    Cohort 6- Dexmedetomidine (240 Micrograms) vs. Placebo

    Sublingual film containing 240 Micrograms Dexmedetomidine or Placebo Sublingual film

    Drug: Dexmedetomidine · Drug: Placebo

Interventions

  • Sublingual Film of Dexmedetomidine

    Also known as: BXCL501

  • DrugPlacebo

    Sublingual Placebo film

    Also known as: Placebo comparator

06

What researchers measure

Primary outcomes

  1. Peak SOWS Scores at Baseline and Over Time

    Short Opiate Withdrawal Scale (SOWS)-Gossop: The SOWs scale is a validated 10-item patient-reported scale designed to measure the symptoms of withdrawal in subjects who are dependent on opioids. Each of the 10 items represents a symptom: "feeling sick," "stomach cramps," "muscle spasms/twitching," "feeling of coldness," "heart pounding," "muscular tension," "aches and pains," "yawning," "runny eyes," and "insomnia/problems sleeping." Scores on the SOWS-Gossop can range from 0 to 30, with higher scores indicating greater severity of withdrawal symptoms.

    Time frame: Baseline (pre-dose day 6) and at days 6, 7, 8, 9, 10, 11, 12, 13, and 14 post-dose

Secondary outcomes

  1. Peak COWS Score at Baseline and Over Time

    Clinical Opiate Withdrawal Scale (COWS): The COWS scale is a validated, 11-item questionnaire designed to quantify withdrawal symptoms. Symptoms evaluated include resting pulse rate, sweating, restlessness, pupil size, bone or joint aches, runny nose or tearing, gastrointestinal upset, tremor, yawning, anxiety or irritability, and gooseflesh. COWS total scores range from 0 to 48, with 5 to 12 indicating mild symptoms, 13 to 24 indicating moderate symptoms, 25 to 36 indicating moderately severe symptoms, and greater than 36 indicating severe symptoms.

    Time frame: Baseline (pre-dose day 6) and at days 6, 7, 8, 9, 10, 11, 12, 13, and 14 post-dose

  2. Average COWS Scores at Baseline and Over Time

    Clinical Opiate Withdrawal Scale (COWS): The COWs scale is a validated, 11-item questionnaire designed to quantify withdrawal symptoms. Symptoms evaluated include resting pulse rate, sweating, restlessness, pupil size, bone or joint aches, runny nose or tearing, gastrointestinal upset, tremor, yawning, anxiety or irritability, and gooseflesh. COWS total scores range from 0 to 48, with 5 to 12 indicating mild symptoms, 13 to 24 indicating moderate symptoms, 25 to 36 indicating moderately severe symptoms, and greater than 36 indicating severe symptoms.

    Time frame: Baseline (pre-dose day 6) and at days 6, 7, 8, 9, 10, 11, 12, 13, and 14 post-dose

  3. Average SOWS at Baseline and Over Time

    Short Opiate Withdrawal Scale (SOWS)-Gossop: The SOWs scale is a validated 10-item patient-reported scale designed to measure the symptoms of withdrawal in subjects who are dependent on opioids.5 Each of the 10 items represents a symptom: "feeling sick," "stomach cramps," "muscle spasms/twitching," "feeling of coldness," "heart pounding," "muscular tension," "aches and pains," "yawning," "runny eyes," and "insomnia/problems sleeping." Scores on the SOWS-Gossop can range from 0 to 30, with higher scores indicating greater severity of withdrawal symptoms.

    Time frame: Baseline (pre-dose day 6) and at days 6, 7, 8, 9, 10, 11, 12, 13, and 14 post-dose

  4. Time to Drop-out After Discontinuation of Opioid Maintenance Phase

    Time to drop-out during double-blind treatment phase after discontinuation of opioid maintenance Phase.

    Time frame: Day 6 through Day 14

  5. Number and Percentage of Subject Drop-out After Discontinuation of Opioid Maintenance Phase Maintenance Within Each Treatment Group

    Number and Percentage of Subject Drop-out after Discontinuation of Opioid Maintenance Phase Within Each Treatment Group Between Days 6-14.

    Time frame: Day 6 through Day 14

  6. Total ACES Total Score Over Time - 2 hr. Post-First Dose

    Overall Agitation-Calmness Evaluation Scale (ACES): The ACES scale is a single-item measure rating overall agitation and sedation, ranging from 1 (marked agitation) to 9 (unarousable). This outcome measures the total ACES total score over time at 2 hours, post-first dose.

    Time frame: Post-Dose Day 6 to Day 12

07

Results

Posted Oct 26, 2023

Participant flow

Opioid Maintenance Phase
Participant flow — Opioid Maintenance Phase
MilestoneMorphine Maintenance, Then Cohort 1- 30 MicrogramsMorphine Maintenance, Then Cohort 2- 60 MicrogramsMorphine Maintenance, Then Cohort 3- 90 MicrogramsMorphine Maintenance, Then Cohort 4- 120 MicrogramsMorphine Maintenance, Then Cohort 5- 180 MicrogramsMorphine Maintenance, Then Cohort 6- 240 MicrogramsMorphine Maintenance, Then Cohort 7- Placebo
Started29353132403325
Completed17172119211525
Not completed1218101319180
Double-blind Treatment Phase
Participant flow — Double-blind Treatment Phase
MilestoneMorphine Maintenance, Then Cohort 1- 30 MicrogramsMorphine Maintenance, Then Cohort 2- 60 MicrogramsMorphine Maintenance, Then Cohort 3- 90 MicrogramsMorphine Maintenance, Then Cohort 4- 120 MicrogramsMorphine Maintenance, Then Cohort 5- 180 MicrogramsMorphine Maintenance, Then Cohort 6- 240 MicrogramsMorphine Maintenance, Then Cohort 7- Placebo
Started17172119211525
Completed7567566
Not completed1012151216919
Withdrew: Adverse event0001000
Withdrew: Lost to follow-up0000100
Withdrew: Withdrawal by subject1012151115919

Outcome measures

PrimaryPeak SOWS Scores at Baseline and Over Time

Short Opiate Withdrawal Scale (SOWS)-Gossop: The SOWs scale is a validated 10-item patient-reported scale designed to measure the symptoms of withdrawal in subjects who are dependent on opioids. Each of the 10 items represents a symptom: "feeling sick," "stomach cramps," "muscle spasms/twitching," "feeling of coldness," "heart pounding," "muscular tension," "aches and pains," "yawning," "runny eyes," and "insomnia/problems sleeping." Scores on the SOWS-Gossop can range from 0 to 30, with higher scores indicating greater severity of withdrawal symptoms.

Time frame:
Baseline (pre-dose day 6) and at days 6, 7, 8, 9, 10, 11, 12, 13, and 14 post-dose
Reported as:
Mean · score on a scale
Peak SOWS Scores at Baseline and Over Time
score on a scale30 Micrograms60 Micrograms90 Micrograms120 Micrograms180 Micrograms240 MicrogramsPooled Placebo
Baseline, Pre-Dose, Day 63.6 ± 3.245.2 ± 3.866.0 ± 5.454.7 ± 4.645.0 ± 4.436.5 ± 7.386.2 ± 6.93
Day 6 Post-dose4.0 ± 3.309.1 ± 7.497.7 ± 5.018.6 ± 7.059.0 ± 7.2011.2 ± 6.277.5 ± 7.08
Day 7 Post-dose8.8 ± 8.199.6 ± 7.099.3 ± 6.1010.7 ± 7.2014.9 ± 9.4214.2 ± 11.1710.2 ± 8.10
Day 8 Post-dose9.8 ± 7.867.4 ± 7.238.6 ± 5.868.0 ± 6.4610.8 ± 7.6312.0 ± 7.599.1 ± 7.50
Day 9 Post-dose6.8 ± 3.356.0 ± 3.276.5 ± 4.726.9 ± 6.4410.2 ± 6.4411.5 ± 9.278.0 ± 9.74
Day 10 Post-dose6.7 ± 6.024.3 ± 2.665.3 ± 5.284.6 ± 5.878.5 ± 5.228.5 ± 5.324.1 ± 3.80
Day 11 Post-dose4.0 ± 3.963.8 ± 4.383.4 ± 3.642.5 ± 2.567.2 ± 6.344.8 ± 3.255.1 ± 8.57
Day 12 Post-dose5.4 ± 5.653.2 ± 3.032.8 ± 3.542.9 ± 3.835.7 ± 5.105.2 ± 3.767.0 ± 11.38
Day 13 Post-dose5.0 ± 4.125.4 ± 6.994.0 ± 3.904.0 ± 4.573.3 ± 2.293.5 ± 1.384.3 ± 6.22
Day 14 Post-dose2.4 ± 2.642.8 ± 3.832.7 ± 3.882.1 ± 2.541.7 ± 2.341.2 ± 1.834.3 ± 9.67
SecondaryPeak COWS Score at Baseline and Over Time

Clinical Opiate Withdrawal Scale (COWS): The COWS scale is a validated, 11-item questionnaire designed to quantify withdrawal symptoms. Symptoms evaluated include resting pulse rate, sweating, restlessness, pupil size, bone or joint aches, runny nose or tearing, gastrointestinal upset, tremor, yawning, anxiety or irritability, and gooseflesh. COWS total scores range from 0 to 48, with 5 to 12 indicating mild symptoms, 13 to 24 indicating moderate symptoms, 25 to 36 indicating moderately severe symptoms, and greater than 36 indicating severe symptoms.

Time frame:
Baseline (pre-dose day 6) and at days 6, 7, 8, 9, 10, 11, 12, 13, and 14 post-dose
Reported as:
Mean · score on a scale
Peak COWS Score at Baseline and Over Time
score on a scale30 Micrograms60 Micrograms90 Micrograms120 Micrograms180 Micrograms240 MicrogramsPooled Placebo
Baseline (Pre-Dose, Day 6)2.4 ± 1.774.6 ± 3.545.2 ± 3.874.1 ± 2.684.4 ± 3.073.8 ± 2.762.7 ± 2.49
Day 6 Post dose4.2 ± 2.776.7 ± 3.164.6 ± 2.284.1 ± 2.565.4 ± 3.176.7 ± 3.835 ± 2.83
Day 7 Postdose8.8 ± 5.376.1 ± 3.736.1 ± 2.326.5 ± 3.077.4 ± 3.657.3 ± 4.296.1 ± 3.25
Day 8 Postdose8.9 ± 5.544.3 ± 3.46.1 ± 3.934.8 ± 2.866.8 ± 3.646.0 ± 4.295.9 ± 3.61
Day 9 Postdose6.2 ± 3.804.7 ± 1.984.7 ± 2.543.5 ± 2.227.0 ± 3.306.8 ± 3.016.0 ± 6.14
Day 10 Postdose4.9 ± 3.673.5 ± 1.523.7 ± 2.563.5 ± 2.074.6 ± 1.913.8 ± 1.473.9 ± 2.17
Day 11 Postdose5.4 ± 4.285.0 ± 5.832.0 ± 1.633.4 ± 2.204.5 ± 3.333.5 ± 2.263.0 ± 2.83
Day 12 Postdose3.6 ± 2.074.6 ± 4.282.0 ± 1.102.4 ± 1.773.6 ± 2.463.3 ± 1.754.5 ± 4.76
Day 13 Postdose5.3 ± 2.934.0 ± 3.674.2 ± 2.932.5 ± 1.772.6 ± 1.273.0 ± 2.103.2 ± 3.97
Day 14 Postdose3.4 ± 1.993.2 ± 2.172.8 ± 2.321.4 ± 1.622.3 ± 1.373.3 ± 2.423.5 ± 3.56
SecondaryAverage COWS Scores at Baseline and Over Time

Clinical Opiate Withdrawal Scale (COWS): The COWs scale is a validated, 11-item questionnaire designed to quantify withdrawal symptoms. Symptoms evaluated include resting pulse rate, sweating, restlessness, pupil size, bone or joint aches, runny nose or tearing, gastrointestinal upset, tremor, yawning, anxiety or irritability, and gooseflesh. COWS total scores range from 0 to 48, with 5 to 12 indicating mild symptoms, 13 to 24 indicating moderate symptoms, 25 to 36 indicating moderately severe symptoms, and greater than 36 indicating severe symptoms.

Time frame:
Baseline (pre-dose day 6) and at days 6, 7, 8, 9, 10, 11, 12, 13, and 14 post-dose
Reported as:
Mean · score on a scale
Average COWS Scores at Baseline and Over Time
score on a scale30 Micrograms60 Micrograms90 Micrograms120 Micrograms180 Micrograms240 MicrogramsPooled Placebo
Baseline (Pre-Dose, Day 6)2.41 ± 1.7704.59 ± 3.5375.19 ± 3.8684.05 ± 2.6774.38 ± 3.0743.80 ± 2.7572.71 ± 2.493
Day 6, Post-Dose3.21 ± 1.9135.22 ± 3.1733.85 ± 2.2543.26 ± 2.2874.29 ± 2.8534.83 ± 2.8144.02 ± 2.477
Day 7 Post dose6.19 ± 4.0135.63 ± 3.5624.92 ± 2.3905.08 ± 2.8496.41 ± 3.2056.04 ± 4.1094.54 ± 2.349
Day 8 Post dose7.19 ± 4.4893.21 ± 2.7975.19 ± 3.6463.70 ± 2.1635.81 ± 3.3914.40 ± 2.5695.14 ± 3.359
Day 9 Post dose5.11 ± 3.4623.50 ± 1.7804.20 ± 2.4402.80 ± 1.8595.63 ± 2.9705.25 ± 2.4785.39 ± 6.279
Day 10 Post dose3.43 ± 2.9923.17 ± 1.6933.07 ± 2.1102.70 ± 1.8843.82 ± 1.6472.67 ± 1.2522.81 ± 1.731
Day 11 Postdose3.57 ± 2.5893.30 ± 3.0541.50 ± 1.2582.69 ± 2.0863.59 ± 2.7822.58 ± 1.5302.50 ± 2.799
Day 12 Post dose3.07 ± 2.2633.30 ± 2.8641.42 ± 1.0681.81 ± 1.4383.14 ± 2.5212.58 ± 1.7153.58 ± 4.364
Day 13 Post dose4.07 ± 2.3353.20 ± 3.8832.58 ± 1.5942.13 ± 1.8471.71 ± 1.0352.50 ± 1.5492.58 ± 3.247
Day 14 Post dose3.43 ± 1.9882.70 ± 1.9241.92 ± 1.2011.21 ± 1.4682.33 ± 1.3663.00 ± 1.8973.33 ± 3.204
SecondaryAverage SOWS at Baseline and Over Time

Short Opiate Withdrawal Scale (SOWS)-Gossop: The SOWs scale is a validated 10-item patient-reported scale designed to measure the symptoms of withdrawal in subjects who are dependent on opioids.5 Each of the 10 items represents a symptom: "feeling sick," "stomach cramps," "muscle spasms/twitching," "feeling of coldness," "heart pounding," "muscular tension," "aches and pains," "yawning," "runny eyes," and "insomnia/problems sleeping." Scores on the SOWS-Gossop can range from 0 to 30, with higher scores indicating greater severity of withdrawal symptoms.

Time frame:
Baseline (pre-dose day 6) and at days 6, 7, 8, 9, 10, 11, 12, 13, and 14 post-dose
Reported as:
Mean · score on a scale
Average SOWS at Baseline and Over Time
score on a scale30 Micrograms60 Micrograms90 Micrograms120 Micrograms180 Micrograms240 MicrogramsPooled Placebo
Baseline, Pre-Dose, Day 63.59 ± 3.2425.18 ± 3.8615.95 ± 5.4544.74 ± 4.6414.95 ± 4.4336.53 ± 7.3766.21 ± 6.934
Day 6 Postdose3.35 ± 3.0717.13 ± 6.6175.88 ± 3.9165.79 ± 4.3886.81 ± 5.8158.50 ± 4.9356.58 ± 6.780
Day 7 Postdose6.73 ± 5.4268.83 ± 6.9597.39 ± 4.5138.42 ± 6.38011.53 ± 7.70210.63 ± 9.6707.54 ± 5.458
Day 8 Postdose8.65 ± 7.9674.86 ± 4.6167.63 ± 5.6146.85 ± 5.9919.31 ± 7.76510.15 ± 8.2677.92 ± 6.828
Day 9 Postdose6.11 ± 3.3614.14 ± 2.4285.65 ± 4.4044.95 ± 5.3258.21 ± 4.3989.00 ± 7.5217.06 ± 9.318
Day 10 Postdose4.79 ± 4.0303.33 ± 2.2064.57 ± 4.4573.50 ± 5.2176.59 ± 3.7405.08 ± 2.1783.06 ± 3.076
Day 11 Postdose2.79 ± 2.4642.20 ± 2.4143.00 ± 3.6511.94 ± 2.1955.18 ± 5.1393.42 ± 2.2233.50 ± 6.110
Day 12 Postdose4.00 ± 4.2522.20 ± 2.1682.00 ± 2.3872.19 ± 3.2944.77 ± 4.9673.67 ± 2.6964.58 ± 6.953
Day 13 Postdose3.93 ± 2.7754.70 ± 7.0682.08 ± 1.8823.31 ± 3.8912.21 ± 1.5422.50 ± 1.0493.25 ± 5.760
Day 14 Postdose2.43 ± 2.6372.40 ± 3.3621.67 ± 2.2511.71 ± 2.2701.67 ± 2.3381.08 ± 1.6862.92 ± 6.216
SecondaryTime to Drop-out After Discontinuation of Opioid Maintenance Phase

Time to drop-out during double-blind treatment phase after discontinuation of opioid maintenance Phase.

Time frame:
Day 6 through Day 14
Reported as:
Median · Days
Time to Drop-out After Discontinuation of Opioid Maintenance Phase
Days30 Micrograms60 Micrograms90 Micrograms120 Micrograms180 Micrograms240 MicrogramsPooled Placebo
Time to Drop-out After Discontinuation of Opioid Maintenance Phase3.1 (0.7 to NA)1.5 (0.00 to NA)3.1 (2.2 to 6.0)5.1 (1.1 to NA)6.1 (2.1 to NA)3.5 (1.0 to NA)2.0 (0.7 to 5.1)
SecondaryNumber and Percentage of Subject Drop-out After Discontinuation of Opioid Maintenance Phase Maintenance Within Each Treatment Group

Number and Percentage of Subject Drop-out after Discontinuation of Opioid Maintenance Phase Within Each Treatment Group Between Days 6-14.

Time frame:
Day 6 through Day 14
Reported as:
Count of participants · Participants
Number and Percentage of Subject Drop-out After Discontinuation of Opioid Maintenance Phase Maintenance Within Each Treatment Group
Participants30 Micrograms60 Micrograms90 Micrograms120 Micrograms180 Micrograms240 MicrogramsPooled Placebo
Day 63433327
Day 71525244
Day 83041414
Day 93050112
Day 100200010
Day 110002002
Day 120010200
Day 130001200
Day 140000100
SecondaryTotal ACES Total Score Over Time - 2 hr. Post-First Dose

Overall Agitation-Calmness Evaluation Scale (ACES): The ACES scale is a single-item measure rating overall agitation and sedation, ranging from 1 (marked agitation) to 9 (unarousable). This outcome measures the total ACES total score over time at 2 hours, post-first dose.

Time frame:
Post-Dose Day 6 to Day 12
Reported as:
Mean · units on a scale
Total ACES Total Score Over Time - 2 hr. Post-First Dose
units on a scale30 Micrograms60 Micrograms90 Micrograms120 Micrograms180 Micrograms240 MicrogramsPooled Placebo
Day 6, Post-Dose4.6 ± 1.273.4 ± 1.714.4 ± 1.354.9 ± 1.314.7 ± 1.354.9 ± 1.734.3 ± 1.40
Day 7, Post-Dose4.3 ± 0.953.6 ± 1.833.8 ± 1.293.9 ± 0.764.1 ± 1.484.4 ± 1.734.1 ± 0.86
Day 8, Post-Dose3.8 ± 1.174.1 ± 1.074.0 ± 1.264.6 ± 1.434.2 ± 1.175.0 ± 1.834.1 ± 0.83
Day 9, Post-Dose3.0 ± 0.874.1 ± 1.463.7 ± 0.674.5 ± 1.183.5 ± 0.804.7 ± 2.063.8 ± 0.46
Day 10, Post-Dose4.1 ± 1.773.8 ± 0.984.1 ± 0.384.3 ± 1.064.3 ± 1.014.3 ± 1.374.4 ± 0.92
Day 11, Post-Dose4.7 ± 1.504.0 ± 0.714.1 ± 0.384.1 ± 0.643.9 ± 0.944.2 ± 0.414.6 ± 1.13
Day 12, Post-Dose4.3 ± 0.764.4 ± 1.44.7 ± 1.214.0 ± 0.004.1 ± 0.834.8 ± 1.334.0 ± 1.10

Adverse events

Collected over 9 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
30 Micrograms0/17 (0%)0/17 (0%)1/17 (5.9%)
60 Micrograms0/17 (0%)0/17 (0%)5/17 (29.4%)
90 Micrograms0/21 (0%)0/21 (0%)2/21 (9.5%)
120 Micrograms0/19 (0%)0/19 (0%)4/19 (21.1%)
180 Micrograms0/21 (0%)0/21 (0%)8/21 (38.1%)
240 Micrograms0/15 (0%)0/15 (0%)9/15 (60%)
Pooled Placebo0/25 (0%)0/25 (0%)5/25 (20%)
Most frequent other events
Showing 10 of 25
Most frequent other events
Event30 Micrograms60 Micrograms90 Micrograms120 Micrograms180 Micrograms240 MicrogramsPooled Placebo
SomnolenceNervous system disorders0/170/170/210/192/217/150/25
HypotensionVascular disorders0/171/170/210/190/215/150/25
Orthostatic HypotensionVascular disorders0/170/170/210/192/214/150/25
VomitingGastrointestinal disorders0/171/170/211/191/213/150/25
CoughRespiratory, thoracic and mediastinal disorders0/170/170/211/193/210/151/25
DiarrhoeaGastrointestinal disorders1/172/170/211/190/211/153/25
AnxietyPsychiatric disorders0/172/170/210/191/210/150/25
IrritabilityPsychiatric disorders0/172/170/210/190/210/150/25
NauseaGastrointestinal disorders0/171/171/211/192/211/151/25
BradycardiaCardiac disorders0/170/170/210/190/211/150/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1- 30 MicrogramsCohort 2- 60 MicrogramsCohort 3- 90 MicrogramsCohort 4- 120 MicrogramsCohort 5- 180 MicrogramsCohort 6- 240 MicrogramsPooled PlaceboTotal
Mean41.6 ± 13.8845.5 ± 12.5639.3 ± 9.6441.3 ± 9.5542.9 ± 9.5742.0 ± 11.8642.1 ± 10.9742.0 ± 10.99
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1- 30 MicrogramsCohort 2- 60 MicrogramsCohort 3- 90 MicrogramsCohort 4- 120 MicrogramsCohort 5- 180 MicrogramsCohort 6- 240 MicrogramsPooled PlaceboTotal
Female682464636
Male119191515111999
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1- 30 MicrogramsCohort 2- 60 MicrogramsCohort 3- 90 MicrogramsCohort 4- 120 MicrogramsCohort 5- 180 MicrogramsCohort 6- 240 MicrogramsPooled PlaceboTotal
Hispanic or Latino105244218
Not Hispanic or Latino16171617171123117
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1- 30 MicrogramsCohort 2- 60 MicrogramsCohort 3- 90 MicrogramsCohort 4- 120 MicrogramsCohort 5- 180 MicrogramsCohort 6- 240 MicrogramsPooled PlaceboTotal
American Indian or Alaska Native00000000
Asian00000000
Native Hawaiian or Other Pacific Islander00000000
Black or African American7104675948
White107161213101684
More than one race00010001
Unknown or Not Reported00101002
Height
Height(cm)Cohort 1- 30 MicrogramsCohort 2- 60 MicrogramsCohort 3- 90 MicrogramsCohort 4- 120 MicrogramsCohort 5- 180 MicrogramsCohort 6- 240 MicrogramsPooled PlaceboTotal
Mean170.32 ± 6.933170.14 ± 7.255176.46 ± 10.176171.57 ± 10.942172.25 ± 10.349174.17 ± 7.998174.42 ± 9.220172.92 ± 9.283
Weight
Weight(kg)Cohort 1- 30 MicrogramsCohort 2- 60 MicrogramsCohort 3- 90 MicrogramsCohort 4- 120 MicrogramsCohort 5- 180 MicrogramsCohort 6- 240 MicrogramsPooled PlaceboTotal
Mean71.22 ± 10.60466.38 ± 10.15978.05 ± 13.82782.04 ± 17.99983.65 ± 26.18983.51 ± 21.31379.23 ± 21.48077.98 ± 19.085
Body Mass Index
Body Mass Index(kg/m^2)Cohort 1- 30 MicrogramsCohort 2- 60 MicrogramsCohort 3- 90 MicrogramsCohort 4- 120 MicrogramsCohort 5- 180 MicrogramsCohort 6- 240 MicrogramsPooled PlaceboTotal
Mean24.65 ± 4.13522.95 ± 3.21725.05 ± 3.82428.16 ± 7.85628.05 ± 8.24827.47 ± 6.58926.21 ± 7.72126.12 ± 6.498
08

Study locations

3 sites
  • BioXcel Clinical Research Site
    Miami Lakes, Florida 33016, United States
  • BioXcel Clinical Research Site
    Marlton, New Jersey 08053, United States
  • BioXcel Clinical Research Site
    New York, New York 10032, United States
09

References and documents

Publications

  • Jones JD, Rajachandran L, Yocca F, Risinger R, De Vivo M, Sabados J, Levin FR, Comer SD. Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial. Am J Drug Alcohol Abuse. 2023 Jan 2;49(1):109-122. doi: 10.1080/00952990.2022.2144743. Epub 2023 Jan 11. PubMed 36630319 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — The Study Protocol and Statistical Analysis Plan (SAP) will be shared. Individual data is summarized by treatment group.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Feb 2021, 8 months.

Results were first posted in Oct 2023, 2 years 8 months after primary completion.

Of 14 phase 1/2 interventional studies under Opioid-Related Disorders, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 37. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2020
First posted
Jul 14, 2020
StartActual
Jun 9, 2020
Primary completionActual
Feb 18, 2021
CompletionActual
Feb 18, 2021
Results first posted
Oct 26, 2023
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04470050
Lead sponsor
BioXcel Therapeutics Inc
Collaborators
Cognitive Research Corporation
Responsible party
Sponsor
First posted
Jul 14, 2020
Start date
Jun 9, 2020
Primary completion
Feb 18, 2021
Completion
Feb 18, 2021
Results posted
Oct 26, 2023
Last update
Aug 11, 2026

Study contacts

BioXcel MM, MD
study director · BioXcel Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion